
Lanell M PetersonUniversity of Washington | UW · Department of Radiology
Lanell M Peterson
About
96
Publications
5,919
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
4,973
Citations
Introduction
Skills and Expertise
Publications
Publications (96)
Background ¹⁸ F-Fluorodeoxyglucose (FDG) and ¹⁸ F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients with hormone-receptor (HR) positive metastatic breast cancer (MBC), but little is known about its u...
Background
Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients that have bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deo...
BACKGROUND
Standard measures of response such as Response Evaluation Criteria in Solid Tumors are ineffective for bone lesions, often making breast cancer patients with bone-dominant metastases ineligible for clinical trials with potentially helpful therapies. In this study we prospectively evaluated the test-retest uptake variability of 2-deoxy-2-...
Purpose
To investigate combined MRI and ¹⁸F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathological response and recurrence-free survival (RFS) in women treated for breast cancer.
Methods
Patients undergoing neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer were imaged at three timepoints (pre,...
Background: 18F-Fluorodeoxyglucose (FDG) has long been used for measuring tumor glycolytic activity in clinical PET imaging. The FDA recently approved 18F-Fluoroestradiol (FES) (Cerianna) as a PET imaging tracer for characterizing disease in patients with estrogen-receptor positive (ER+) breast cancer. As FES PET enters clinical practice it is impo...
Background: 18F-FES is an FDA-approved estrogen analogue PET imaging tracer (Cerianna) which measures tumor estrogen receptor (ER) expression at multiple tumor sites simultaneously and predicts response to endocrine therapy. 18F-FDG is a commonly used glucose PET imaging tracer which measures glycolytic metabolic activity in tumors. Elevated plasma...
PET imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES), a radiolabeled form of estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is approved by the U.S. Food and Drug Administration as a diagnostic agent "for the detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metas...
1042
Background: The recently FDA approved ¹⁸ F-Fluoroestradiol (FES) is a PET imaging tracer for characterizing disease in patients with ER+ breast cancer. As FES PET enters clinical practice it will be important to establish its utility in the full population of hormone-receptor positive patients, including those with HER2+ tumors. Historically t...
PurposeProbe-based dynamic (4-D) imaging modalities capture breast intratumor heterogeneity both spatially and kinetically. Characterizing heterogeneity through tumor sub-populations with distinct functional behavior may elucidate tumor biology to improve targeted therapy specificity and enable precision clinical decision making.Methods
We propose...
A Correction to this paper has been published: 10.1007/s00259-021-05324-0
Purpose
This study evaluated the ability of ¹⁸ F-Fluorodeoxyglucose (FDG) and ¹⁸ F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors.
Methods
In two separate studies, women with earl...
Background: The histology and pattern of spread in lobular breast cancer has presented challenges in estimating extent of disease by traditional imaging methods. ¹⁸F-FES is an estrogen analogue PET imaging tracer which measures tumor ER expression at multiple tumor sites simultaneously. It is FDA approved in the US and will be available in 2021, pr...
Rationale:
Histone deacetylase inhibitors (HDACi) may overcome endocrine resistance in estrogen receptor positive (ER+) metastatic breast cancer. We tested whether 18F-Fluoroestradiol (18F-FES)-PET imaging would elucidate pharmacodynamics of combination HDACi and endocrine therapy. Methods: Patients with ER+/HER2- metastatic breast cancer with pri...
e12573
Background: Breast cancer heterogeneity is thought to be associated with adverse outcomes. Dynamic molecular imaging modalities, including PET, permit 4-D sampling of tumor biologic properties and can therefore capture functional heterogeneity revealed by the temporal dimension of the dynamic tracer uptake. With the goal of improved non-inva...
Background: Bone dominant metastatic breast cancer can be difficult to stage using conventional imaging. ¹⁸F-FES is an estrogen analogue PET imaging tracer that measures estrogen receptor (ER) expression at multiple tumor sites simultaneously and predicts response to endocrine therapy. We analyzed FES-PET and FDG-PET SUV uptake within bone in patie...
Background: The histology and pattern of spread in lobular breast cancer has presented challenges in estimating extent of disease and identifying treatment options. ¹⁸F-FES is an estrogen analogue PET imaging tracer which measures tumor ER expression at multiple tumor sites simultaneously and predicts response to endocrine therapy. We analyzed FES-...
Calibration and reproducibility of quantitative 18F-fluorodeoxyglucose (FDG) PET measures are essential for adopting integral FDG-PET/CT biomarkers and response measures in multicenter clinical trials. We implemented a multicenter qualification process using NIST-traceable reference sources for scanners and dose calibrators, and similar patient and...
Two data points from Table 1. (continued) were published in error. The corrected data in Table 1. (continued) are shown, in italic, below.
Molecular imaging using 16α-[¹⁸F]fluoro-17β-estradiol (FES) and ¹⁸F-fluoro-furanyl-norprogesterone PET can assess in vivo function of steroid hormone receptors in breast cancer. These experimental agents have been tested in many single-center clinical trials and show promise to elucidate prognosis and predict endocrine therapy response. The current...
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial 18F-FDG PET was predictive of time to skeletal related events (tSRE) and time-to-progression (TTP). 18F-NaF PET improves bone metastasis detection compared to bone scans. We prospectively tested 18F-FDG PET and 18F-NaF PET to predict tSRE, T...
Blood flow-metabolism mismatch from dynamic positron emission tomography (PET) studies with [Formula: see text]-labeled water ([Formula: see text]) and [Formula: see text]-labeled fluorodeoxyglucose (FDG) has been shown to be a promising diagnostic for locally advanced breast cancer (LABCa) patients. The mismatch measurement involves kinetic analys...
11572
Background: ¹⁸ F-Fluoroestradiol (FES) is an estrogen analogue that has been shown to be a promising biomarker in ER imaging of breast cancer. FES uptake correlates to ER expression, provides qualitative and quantitative assessment of multiple tumor sites simultaneously, and can predict response to endocrine therapies. Tumor heterogeneity is...
Objective:
We developed a method to evaluate variations in the PET imaging process in order to characterize the relative ability of static and dynamic metrics to measure breast cancer response to therapy in a clinical trial setting.
Methods:
We performed a virtual clinical trial by generating 540 i.i.d. PET imaging study realizations for each of...
Background: Metabolic activity in lesions, measured by FDG-PET, is often used for assessing tumor aggressiveness and response to therapy. Patients may be scanned on different machines, so quantitative measurements should be reproducible. Reducing SUV variability in PET machines throughout a local network can aid in monitoring patient response to th...
Prior reports have suggested that delayed 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) oncology imaging can improve the contrast-to-noise ratio (CNR) for known lesions. Our goal was to estimaterealistic bounds for lesion detectability for static measurements within 1 to 4 hours between FDG injectionand image acquisition. Tumor and...
Purpose:
18F-fluoroestradiol (FES) positron emission tomography (PET) scans measure regional estrogen binding, and 18F-fluorodeoxyglucose (FDG) PET measures tumor glycolytic activity. We examined quantitative and qualitative imaging biomarkers of progression-free survival in breast cancer patients receiving endocrine therapy.
Experimental design:...
Background: Using quantitative FDG PET to measure glucose metabolism and perfusion, and dynamic contrast-enhanced (DCE) MRI to measure perfusion, we previously identified a metabolic signature for breast cancer resistant to NAC. This imaging signature is (1) persistent or increased tumor perfusion despite treatment, (2) an altered pattern of glucos...
Changes in estrogen receptor (ER) expression over the course of therapy may affect response to endocrine therapy. However, measuring temporal changes in ER expression requires serial biopsies, which are impractical and poorly tolerated by most patients. Functional ER imaging using 18F-fluoroestradiol (FES)-PET provides a noninvasive measure of regi...
Methods:
Tumor kinetic parameters were estimated from dynamic (18)F-FDG PET scans of breast cancer patients and used to simulate time-activity curves (TACs) for 45-120 minutes post-injection. Five-minute uptake time frames followed four scenarios: (#1) standardized static measurement time (60-65 minutes for all), (#2) uptake times sampled from an...
Prior reports have suggested that delayed FDG-PET oncology imaging can improve the contrast-to-noise ratio (CNR) for known lesions. Our goal was to estimate realistic bounds for lesion detectability for static measurements with one to four hours between FDG injection and image acquisition. Tumor and normal tissue kinetic model parameters were estim...
(18)F-FMISO is the most widely used PET agent for imaging hypoxia, a condition associated with resistance to tumor therapy. (18)F-FMISO equilibrates in normoxic tissues, but is retained under hypoxic conditions because of reduction and binding to macromolecules. A simple tissue-to-blood ratio (TB) is suitable for quantifying hypoxia. A threshold of...
Introduction
Breast cancer is a common, treatable malignancy, with frequent metastasis to bone. Patients with bone-dominant disease are often excluded from clinical trials due to a lack of RECIST "measurable" disease. FDG-PET can help quantitatively measure multiple tumor sites, and assay disease activity in bone. However, the reproducibility of FD...
Background: In estrogen receptor positive (ER+) tumors, a low proliferative index (Ki-67) two weeks into endocrine therapy predicts response. FLT PET non-invasively measures tumor proliferation in vivo. The pre-operative window is an opportunity to assess impact of systemic therapies. We tested associations between FLT PET qualitative and quantitat...
Background: Histone deacetylase inhibitors (HDACi) have shown pre-clinical promise in estrogen receptor(ER)-modulation and restoring sensitivity to endocrine manipulation, suggesting potential clinical benefit (Sabnis 2011) (Huang 2000) in ER+ breast cancer. Vorinostat is an FDA-approved HDACi for CTCL, and could have a beneficial role in restoring...
Background : Assessing response to therapy in patients (pts) with bone-dominant (BD) metastatic breast cancer is challenging by conventional imaging such as CT and bone scintigraphy. In prior retrospective analyses, measures of FDG uptake by FDG PET were predictive of both time to progression (TTP) and the risk of skeletal related events (SRE). Stu...
16α-[(18)F]-fluoro-17β-estradiol positron emission tomography (FES-PET) quantifies estrogen receptor (ER) expression in tumors and may provide diagnostic benefit.
Women with newly diagnosed metastatic breast cancer (MBC) from an ER-positive primary tumor were imaged before starting endocrine therapy. FES uptake was evaluated qualitatively and quant...
s: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX
Background: Some estrogen receptor-positive (ER+) metastatic breast cancers are bone and soft tissue dominant, indolent, and controlled by endocrine therapy. However, these tumors eventually become refractory to endocrine therapy and need a mechan...
In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts recurrence-free survival but is invasive and prone to sampling error. [18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) has shown an early agonist or 'flare' response to tamoxifen and estradiol, but has not been tested in response to estrogen-low...
TPS3109
Background: Endocrine refractory,Indolent, soft tissue, and bone dominant metastatic breast cancer is a clinical problem, for which alternatives to chemotherapy are needed, Histone deacetylace inhibitors (HDACi) have shown pre-clinical promise in estrogen receptor-modulation and restoring sensitivity to endocrine manipulation, suggesting po...
Background: In estrogen receptor positive (ER+) tumors, a low proliferative index (Ki-67) two weeks into endocrine therapy predicts response. FDG PET non-invasively measures tumor sites in vivo. The pre-operative window is an opportunity to assess impact of systemic therapies. We tested associations between FDG PET standardized uptake value (SUV) a...
(18)F-Fluoroestradiol (FES) PET imaging provides a non-invasive method to measure estrogen receptor (ER) expression in tumors. Assessment of factors that could affect the quantitative level of FES uptake is important as part of the validation of FES PET for evaluating regional ER expression in breast cancer.
This study examines FES uptake in tumors...
Heterogeneity of estrogen receptor (ER) expression may be an important predictor of breast cancer therapeutic response. (18)F-fluoroestradiol PET produces in vivo quantitative measurements of regional estrogen binding in breast cancer tumors. We describe within-patient (site-to-site) and between-patient heterogeneity of lesions in patients schedule...
Positron emission tomography (PET) imaging with [F-18] fluoromisonidazole (FMISO) has been validated as a hypoxic tracer. Head and neck cancer exhibits hypoxia, inducing aggressive biologic traits that impart resistance to treatment. Delivery of modestly higher radiation doses to tumors with stable areas of chronic hypoxia can improve tumor control...
To determine, by molecular imaging, how in vivo pharmacodynamics of estrogen-estrogen receptor (ER) binding differ between types of standard endocrine therapy.
The ER has been a highly successful target for breast cancer treatment. ER-directed treatments include lowering ligand concentration by using aromatase inhibitors (AI) and blocking the recep...
The most common site of metastasis for breast cancer is bone. Quantitative (18)F-fluoride PET can estimate the kinetics of fluoride incorporation into bone as a measure of fluoride transport, bone formation, and turnover. The purpose of this analysis was to evaluate the accuracy and precision of (18)F-fluoride model parameter estimates for characte...
11075
Background: Early decline in proliferative index (Ki-67) predicts response to endocrine therapy. For estrogen receptor positive (ER+) tumors, a low Ki-67 two weeks into endocrine therapy also predicts response (Dowsett JNCI 2007). FDG PET is promising for evaluating early response to systemic therapy and has the advantage of being non-invasiv...
The PET compound (18)F-fluoroestradiol ((18)F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. (18)F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to...
14110
Background: Many clinical options are available for management of hormone sensitive breast cancer, including agents which lower estrogen levels such as aromatase inhibitors (AIs) and agents with block ligand binding to receptor such as tamoxifen (TAM) or fulvestrant (FUL). Estrogen receptor (ER) function is essential for sensitivity to hormon...
A prototype blood plasma processor unit was designed and tested for generic PET-tracer metabolite analyses, using solid-phase-extraction cartridges (SepPaks). An assay method for FLT (3′-deoxy-3′-[F-18]fluorothymidine) and its blood metabolite: FLT-glucuronide, in serial, patient-derived samples was developed to evaluate the device. The unit is sim...
The response of cancer to chemotherapy can be quantified using (18)F-FDG to indicate changes in tumor metabolism. Quantification using the standardized uptake value (SUV) is more feasible for clinical practice than is the metabolic rate of (18)F-FDG (MRFDG), which requires longer, dynamic scanning. The relationship between MRFDG and SUV depends in...
18F-FLT is a novel PET radiotracer which has demonstrated a strong potential utility for imaging cellular proliferation in human tumors in vivo. To facilitate future regulatory approval of 18F-FLT for clinical use, we wished to demonstrate the safety of radiotracer doses of 18F-FLT administered to human subjects, by: 1) performing an evaluation of...
Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of...
In breast cancer, [(18)F]fluoroestradiol (FES) positron emission tomography (PET) correlates with estrogen receptors (ER) expression and predicts response to tamoxifen. We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromat...
566
Background: The estrogen receptor (ER) is an essential target for endocrine therapy in breast cancer. We, and others, have tested an in vivo assay of ER function, [F-18]-16α-fluoroestradiol (FES) PET, which allows assessment of all sites of tumor spread and predicts response to hormonal therapy. However, not all patients with tumors bearing fun...
Assessing cellular proliferation provides a direct method to measure the in vivo growth of cancer. We evaluated the application of a model of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) kinetics described in a companion report to the analysis of FLT PET image data in lung cancer patients. Compartmental model analysis was performed to estimate the...
The aim of this study is to compare glucose metabolism and hypoxia in four different tumor types using positron emission tomography (PET). (18)F-labeled fluorodeoxyglucose (FDG) evaluates energy metabolism, whereas the uptake of (18)F-labeled fluoromisonidazole (FMISO) is proportional to tissue hypoxia. Although acute hypoxia results in accelerated...
3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a PET imaging agent that shows promise for studying cellular proliferation in human cancers. FLT is a nucleoside analog that enters cells and is phosphorylated by human thymidine kinase 1, but the 3' substitution prevents further incorporation into DNA. We estimated the radiation dosimetry for this t...
Hypoxia imparts resistance to radiotherapy and chemotherapy and also promotes a variety of changes in tumor biology through inducible promoters. The purpose of this study was to evaluate the use of positron emission tomography (PET) imaging with fluorine-18 fluoromisonidazole (FMISO) in soft tissue sarcomas (STS) as a measure of hypoxia and to comp...
Tumor proliferation has prognostic value in resected early stage non-small cell lung cancer (NSCLC) and can, therefore, predict which NSCLCs are at high risk for recurrence after resection and would benefit from additional therapy. It may also predict which tumor will respond to cell cycle-targeted chemotherapy and help assess the tumor response, b...
[18F]16alpha-fluoroestradiol (FES) is a PET imaging agent useful for the study of estrogen receptors in breast cancer. We estimated the radiation dosimetry for this tracer using data obtained in patient studies.
Time-dependent tissue concentrations of radioactivity were determined from blood samples and PET images in 49 patients (52 studies) after...
Quantitative analysis of [(18)F]-fluoro-deoxyglucose (FDG) uptake is important in oncologic positron emission tomography (PET) studies to be able to set an objective threshold in determining if a tissue is malignant or benign, in assessing response to therapy, and in attempting to predict the aggressiveness of an individual tumor. The most common m...